Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

7.970
-0.360-4.32%
Volume:1.23M
Turnover:9.73M
Market Cap:7.71B
PE:-56.83
High:8.125
Open:8.115
Low:7.825
Close:8.330
52wk High:15.750
52wk Low:6.230
Shares:967.00M
HK Float Shares:967.00M
Volume Ratio:1.38
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.140
ROE:-9.98%
ROA:-5.47%
PB:3.94
PE(LYR):-56.83
PS:12.73

Loading ...

ALPHAMAB-B Secures Three-Year HKEX Waiver to Appoint Jiang Rui as Joint Company Secretary

Bulletin Express
·
Apr 22

ALPHAMAB-B's KN026 Breast Cancer Trial Results Selected for Oral Presentation at 2026 ASCO Annual Meeting

Stock News
·
Apr 22

Alphamab Oncology: KN026 Phase III Neoadjuvant Breast-Cancer Results Chosen for 2026 ASCO Late-Breaking Oral Session

Bulletin Express
·
Apr 22

Alphamab Oncology says KN026 Phase III neoadjuvant breast cancer results selected for ASCO LBA oral session

Reuters
·
Apr 22

ALPHAMAB-B Shares Surge Over 12% in Morning Session as KN026 Commercialization Nears

Stock News
·
Apr 13

ALPHAMAB-B Announces Appointment of Jiang Rui as Joint Company Secretary

Stock News
·
Apr 08

Alphamab Oncology names Jiang Rui joint company secretary, authorized representative

Reuters
·
Apr 08

Alphamab Oncology Keeps Share Base Steady at 974.29 Million Shares in March; Confirms 25%+ Public Float

Bulletin Express
·
Apr 08

Assessing Alphamab Oncology (SEHK:9966) Valuation After A Mixed Period Of Share Price Returns

Simply Wall St.
·
Apr 07

CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint

MT Newswires Live
·
Apr 01

Stock Track | ALPHAMAB-B Soars 5.13% Intraday After Phase III Breast Cancer Trial Meets Primary Endpoint

Stock Track
·
Apr 01

Alphamab Oncology says Phase III KN026 neoadjuvant HER2+ breast cancer trial meets primary endpoint

Reuters
·
Apr 01

BRIEF-Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary Endpoint

Reuters
·
Mar 31

ALPHAMAB-B (09966): Phase III Trial of KN026 as Neoadjuvant Therapy for HER2-Positive Breast Cancer Meets Primary Endpoint

Stock News
·
Mar 31

Alphamab Oncology - Phase Iii Study of Kn026 With Hb1801 for Her2+ Bc Met Primary Endpoint

THOMSON REUTERS
·
Mar 31

Jefferies Adjusts Alphamab Oncology's Price Target to HK$9.60 From HK$7, Keeps at Buy

MT Newswires Live
·
Mar 30

HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%

Tiger Newspress
·
Mar 27

HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.

Tiger Newspress
·
Mar 26

Alphamab Oncology Posts FY Loss RMB113.9 Million

Reuters
·
Mar 25

ALPHAMAB-B Reports Annual Loss of RMB 114 Million, Shifting from Profit Year-on-Year

Stock News
·
Mar 25